In the US, the prevalence of Alzheimer's affects roughly 4 million, with 360,000 new cases per year - current estimates stand at 13.2 million cases in the US by 2050, unless a cure or prevention is found.(1) Given increasing patient numbers and the limitations of available therapies, the market is an attractive investment with a huge unmet need.